TYRA

TYRA

Tyra Biosciences Inc

Net -23.86%top 1%Rev โ€”top 1%1Y
Hold

Tyra Biosciences develops precision medicines targeting fibroblast growth factor receptor (FGFR) biology, focusing on therapies for oncology and genetic conditions. Its pipeline includes treatments for metastatic urothelial carcinoma and skeletal disorders.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 1 year ago โ†’$2,387today

Score Overview

1 Year
Scoreโ€”
Net Growth-23.86%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-468.32%
Net TrendNever
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Tyra Biosciences Inc fundamental performance

Across Tyra Biosciences Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 26M to -$ 119M. Revenue increased in 0% of the years measured; net income in 0%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 25.30โ€”
1 Year2025-08-12
$ 10.60138.68%
All Time2021-09-15
$ 26.00-2.69%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 148M$ 353M
2025$ 0.00-$ 119M$ 256M
2024$ 0.00-$ 86M$ 341M
2023$ 0.00-$ 69M$ 203M
2022$ 0.00-$ 51M$ 251M
IPO2021$ 0.00-$ 26M$ 302M

Explore beyond TYRA

You're looking at Tyra Biosciences Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies